Business Context and Reporting Period
This Form 10-Q covers Gilead Sciences, Inc. for the three and six months ended June 30, 1999. Gilead is a biopharmaceutical company focused on research and development, with its primary commercial product being VISTIDE (cidofovir) for the treatment of CMV retinitis in AIDS patients. The company operates with an accumulated deficit and relies on product sales, royalties, and contract revenues from collaborations to fund operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1999 | Six Months Ended June 30, 1998 |
|---|---|---|
| Total Revenues | $13.6 million | $20.6 million |
| Net Loss | $(30.8) million | $(22.2) million |
| Net Loss Per Share (Basic/Diluted) | $(1.00) | $(0.74) |
| Research & Development Expenses | $34.0 million | $37.3 million |
| Operating Cash Flow | $(40.3) million (Used) | $(12.5) million (Used) |
| Cash and Short-Term Investments | $240.5 million | $279.9 million (Dec 31, 1998) |
| Long-Term Debt | $0.2 million | $0.6 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 34% year-over-year for the six-month period. This was driven primarily by a significant drop in contract revenue ($9.5 million in 1999 vs. $16.1 million in 1998) due to the timing of milestone payments and expense reimbursements from partner Roche. Product sales and royalties also declined slightly.
- Increased Net Loss: The net loss widened to $30.8 million from $22.2 million in the prior year period, reflecting lower revenues and the inclusion of $1.3 million in merger-related expenses.
- Expense Management: R&D expenses decreased slightly ($3.3 million reduction) due to reduced involvement in Tamiflu development, partially offset by increased spending on adefovir dipivoxil and tenofovir programs. SG&A expenses increased slightly to $15.7 million.
- Cash Position: Cash and short-term investments decreased by $39.4 million from the end of 1998, primarily due to operating cash burn and capital expenditures, partially offset by proceeds from stock issuances.
Outlook, Risks, and Unusual Items
- Merger with NeXstar: On July 29, 1999, Gilead completed a merger with NeXstar Pharmaceuticals, Inc. The transaction is accounted for as a pooling of interests. Significant one-time merger expenses are expected in the third quarter of 1999.
- Preferred Stock Conversion: On July 16, 1999, 1,133,786 shares of Series B Convertible Preferred Stock automatically converted to common stock after the share price exceeded the trigger threshold.
- Product Outlook: VISTIDE sales are expected to continue declining due to improved HIV therapies reducing the incidence of CMV retinitis. The company anticipates continued losses for at least one additional year.
- Risks: Key risks include the uncertainty of clinical trial outcomes, regulatory approvals, and the commercial success of new product candidates. The company also faces Year 2000 compliance risks, though it estimates costs will not be material.
- Liquidity: Management believes existing capital resources are adequate for the foreseeable future, supplemented by potential milestone payments of up to $26.0 million from Roche.
Investor Verification Checklist
- Verify the impact of the NeXstar merger on future financial statements and potential dilution from the stock exchange ratio.
- Confirm the status of Roche milestone payments and the likelihood of achieving the remaining $26.0 million in potential revenue.
- Monitor the clinical trial progress and regulatory status of adefovir dipivoxil (hepatitis B) and tenofovir (HIV).
- Assess the trajectory of VISTIDE sales decline and its impact on long-term revenue stability.
- Review the company's cash burn rate against its current cash reserves to determine runway for operations.